ArticleJournal of magnetic resonance imaging : JMRI2026
5T-Based Glutamate Chemical Exchange Saturation Transfer Imaging for Adult Diffuse Glioma Stratification.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial for "5 T-Based Glutamate Chemical Exchange Saturation Transfer Imaging for Adult Diffuse Glioma Stratification".Journal of magnetic resonance imaging : JMRI · 2026Article
- Repeatability and reproducibility of APT and GluCEST imaging at 5 T: phantom validation and clinical evaluation in patients with brain tumors.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundGlutamate chemical exchange saturation transfer (GLU-CEST) is a non-invasive in vivo approach for glutamate detection, but its performance for glioma evaluation at 5T remains incompletely defined. PURPOSE: To investigate factors influencing 5T GLU-CEST and its diagnostic value in glioma stratification. STUDY TYPE: Prospective. PHANTOM AND POPULATION: Five phantom series (pH 6.2-7.4; glutamate 8-20 mM) and 40 adult-type diffuse glioma patients (49.00 ± 12.26 years; 23 males). FIELDSTRENGTH/SEQUENCE: 5 T, fast spin-echo GLU-CEST and amide proton transfer (APT)-CEST. ASSESSMENT: Phantoms and patients underwent MRI scans; GLU-CEST, APT-CEST, and normalized values (ΔGLU-CEST, ΔAPT-CEST) were quantified. Gliomas were graded by WHO 2-4; IDH status was determined. STATISTICAL TESTS: Spearman correlation, Kruskal-Wallis tests, Mann-Whitney U tests, and weighted DeLong tests; two-sided p < 0.05 was significant.
resultsGLU-CEST signals positively correlated with glutamate and negatively with pH (ρ ≥ 0.893). Significant differences were found in all effects between WHO Grade 2 and 4 gliomas (ΔGLU-CEST: 2.006 [1.143, 2.799] vs. 4.365 [2.974, 5.299]; GLU-CEST: 7.424 [6.679, 7.649] vs. 10.155 [8.098, 11.550]; ΔAPT-CEST: 1.918 [1.258, 2.461] vs. 3.386 [2.682, 4.805]; APT-CEST: 1.961 [1.425, 2.715] vs. 3.333 [2.478, 4.632]), whereas only ΔGLU-CEST and GLU-CEST exhibited significant disparities between Grade 3 and 4 gliomas (ΔGLU-CEST: 2.171 [1.895, 2.862] vs. 4.365 [2.974, 5.299]; GLU-CEST: 7.102 [6.475, 7.259] vs. 10.155 [8.098, 11.550]). In the solid tumor region, all effects demonstrated significant differences between IDH-mutant and IDH wild-type gliomas (ΔGLU-CEST: 2.111 [1.614, 3.110] vs. 4.333 [2.964, 5.405]; GLU-CEST: 7.259 [6.577, 7.726] vs. 10.291 [8.097, 11.634]; ΔAPT-CEST: 2.017 [1.355, 2.718] vs. 3.235 [2.670, 4.735]; APT-CEST: 2.122 [1.680, 2.889] vs. 3.270 [2.450, 4.262]), whereas GLU-CEST outperformed APT-CEST and ΔAPT-CEST in diagnostic efficacy (AUC difference = 0.073 and 0.101). DATA
conclusion5 T GLU-CEST is capable of differentiating between grade 2 and grade 4, as well as grade 3 and grade 4 adult diffuse gliomas, and demonstrates superior performance to APT-CEST in the classification of IDH status. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.